MNPR

SEC source: 0001437749-25-022862 · rdgdoc.xml · nonDerivative · entry 1

STARR CHRISTOPHER M · CIK 0001235470 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,973

F1 · shares: This transaction involved a cash exercise of stock options.

SEC source: 0001437749-25-022863 · rdgdoc.xml · derivative · entry 4

Tsuchimoto Kim R · CIK 0001333516 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,704 shares

Expires 2027-02-20

F4 · derivative.exercise_date: Reflects options to purchase a total of 4,704 shares of common stock granted to Ms. Tsuchimoto on February 20, 2017, for her services as a director and prior officer of Monopar Therapeutics. The options vested 6/48ths upon the 6-month anniversary of the grant date and 1/48th per month thereafter.

SEC source: 0001437749-25-022863 · rdgdoc.xml · derivative · entry 3

Tsuchimoto Kim R · CIK 0001333516 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,200 shares

Expires 2026-04-04

F3 · derivative.exercise_date: Reflects options to purchase a total of 4,200 shares of common stock granted to Ms. Tsuchimoto on April 4, 2016, for her services as a director and prior officer of Monopar Therapeutics.The options vested 6/12ths upon the grant date and 3/12th every 6 months thereafter.

SEC source: 0001437749-25-022863 · rdgdoc.xml · nonDerivative · entry 2

Tsuchimoto Kim R · CIK 0001333516 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,486

F2 · price: The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001437749-25-022863 · rdgdoc.xml · nonDerivative · entry 1

Tsuchimoto Kim R · CIK 0001333516 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,390

F1 · shares: This transaction involved a cash exercise of stock options.

SEC source: 0001437749-25-022861 · rdgdoc.xml · derivative · entry 4

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,800 shares

Expires 2027-02-20

F4 · derivative.exercise_date: Reflects options to purchase up to 16,800 shares of common stock granted to Dr. Robinson on February 20, 2017, for his services as a director and officer of Monopar Therapeutics. The options vested 6/48ths upon the 6-month anniversary of the grant date and 1/48th per month thereafter.

SEC source: 0001437749-25-022861 · rdgdoc.xml · nonDerivative · entry 2

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,472

F2 · price: The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001437749-25-022861 · rdgdoc.xml · nonDerivative · entry 1

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,272

F1 · shares: This transaction involved a cash exercise of stock options.

SEC source: 0001437749-25-021993 · rdgdoc.xml · derivative · entry 3

Cittadine Andrew · CIK 0001863624 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,001

Underlying: Common Stock · 6,863 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units.

F3 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F4 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F5 · derivative.exercise_date: On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F3 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F4 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F5 · derivative.expiration_date: On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

SEC source: 0001437749-25-021993 · rdgdoc.xml · nonDerivative · entry 2

Cittadine Andrew · CIK 0001863624 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,858

F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.

SEC source: 0001437749-25-021993 · rdgdoc.xml · nonDerivative · entry 1

Cittadine Andrew · CIK 0001863624 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,848

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents shares acquired on vesting and settlement of restricted stock units.

SEC source: 0001437749-25-021994 · rdgdoc.xml · derivative · entry 4

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,325

Underlying: Common Stock · 13,344 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units.

F4 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F5 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F6 · derivative.exercise_date: On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F4 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F5 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F6 · derivative.expiration_date: On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

SEC source: 0001437749-25-021994 · rdgdoc.xml · nonDerivative · entry 2

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,472

F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.

SEC source: 0001437749-25-021994 · rdgdoc.xml · nonDerivative · entry 1

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,337

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents shares acquired on vesting and settlement of restricted stock units.

SEC source: 0001437749-25-011068 · rdgdoc.xml · nonDerivative · entry 1

Tactic Pharma LLC · CIK 0001727357 · 10% owner

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

Brown Michael J · CIK 0001035909 · Member of 10% Owner Group

O'Halloran Thomas V. · CIK 0001727481 · Member of 10% Owner Group

Mazar Andrew Paul · CIK 0001727393 · Member of 10% Owner Group

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 822,255

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.86, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein.

SEC source: 0001437749-25-010810 · rdgdoc.xml · nonDerivative · entry 2

Cittadine Andrew · CIK 0001863624 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,985

F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.

SEC source: 0001437749-25-010810 · rdgdoc.xml · nonDerivative · entry 1

Cittadine Andrew · CIK 0001863624 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,729

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents shares acquired on vesting and settlement of restricted stock units.

SEC source: 0001437749-25-010809 · rdgdoc.xml · derivative · entry 4

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,669

Underlying: Common Stock · 4,106 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units.

F4 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F5 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F4 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F5 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

SEC source: 0001437749-25-010809 · rdgdoc.xml · nonDerivative · entry 2

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,993

F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.

SEC source: 0001437749-25-010809 · rdgdoc.xml · nonDerivative · entry 1

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,197

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents shares acquired on vesting and settlement of restricted stock units.

SEC source: 0001437749-25-006724 · rdgdoc.xml · derivative · entry 1

Talukdar Lavina · CIK 0002059193 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,683

Underlying: Common Stock · 5,683 shares

Expires 2035-03-04

F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025

SEC source: 0001437749-25-006735 · rdgdoc.xml · derivative · entry 2

Cittadine Andrew · CIK 0001863624 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,655

Underlying: Common Stock · 40,581 shares

Expires not disclosed

F2 · derivative.exercise_date: RSUs vest 6/48ths on June 30, 2025, and 3/48ths per quarter thereafter.

F2 · derivative.expiration_date: RSUs vest 6/48ths on June 30, 2025, and 3/48ths per quarter thereafter.

SEC source: 0001437749-25-006735 · rdgdoc.xml · derivative · entry 1

Cittadine Andrew · CIK 0001863624 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,445

Underlying: Common Stock · 43,445 shares

Expires 2035-03-04

F1 · derivative.exercise_date: Options Vests 6/48ths on June 30, 2025, and 1/48th per month thereafter.

SEC source: 0001437749-25-006730 · rdgdoc.xml · derivative · entry 1

STARR CHRISTOPHER M · CIK 0001235470 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,365

Underlying: Common Stock · 11,365 shares

Expires 2035-03-04

F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025.

SEC source: 0001437749-25-006726 · rdgdoc.xml · derivative · entry 1

KLAUSNER ARTHUR J · CIK 0001207790 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,365

Underlying: Common Stock · 11,365 shares

Expires 2035-03-04

F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025.

SEC source: 0001437749-25-006723 · rdgdoc.xml · derivative · entry 1

Tsuchimoto Kim R · CIK 0001333516 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,365

Underlying: Common Stock · 11,365 shares

Expires 2035-03-04

F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025.

SEC source: 0001437749-25-006725 · rdgdoc.xml · derivative · entry 1

Anderson Raymond · CIK 0001362489 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,365

Underlying: Common Stock · 11,365 shares

Expires 2035-03-04

F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025

SEC source: 0001437749-25-006736 · rdgdoc.xml · derivative · entry 6

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,775

Underlying: Common Stock · 6,002 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units.

F6 · derivative.exercise_date: Represents vesting of 6,002 restricted stock units on the grant date. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F6 · derivative.expiration_date: Represents vesting of 6,002 restricted stock units on the grant date. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

SEC source: 0001437749-25-006736 · rdgdoc.xml · derivative · entry 5

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,777

Underlying: Common Stock · 79,899 shares

Expires not disclosed

F4 · derivative.exercise_date: 6,002 restricted stock units vested on the grant date. Remainder of restricted stock units vest 6/48ths on June 30, 2025, and 3/48ths per quarter thereafter.

F4 · derivative.expiration_date: 6,002 restricted stock units vested on the grant date. Remainder of restricted stock units vest 6/48ths on June 30, 2025, and 3/48ths per quarter thereafter.

SEC source: 0001437749-25-006736 · rdgdoc.xml · derivative · entry 4

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,759

Underlying: Common Stock · 85,759 shares

Expires 2035-03-04

F3 · derivative.exercise_date: 6,647 options vested on the grant date. Remainder of options vest 6/48ths on June 30, 2025, and 1/48th per month thereafter.

SEC source: 0001437749-25-006736 · rdgdoc.xml · nonDerivative · entry 2

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,091

F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.

SEC source: 0001437749-25-006736 · rdgdoc.xml · nonDerivative · entry 1

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,850

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents shares acquired on vesting and settlement of restricted stock units.

SEC source: 0001437749-25-006297 · rdgdoc.xml · derivative · entry 1

Vu Quan Anh · CIK 0001892297 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2035-03-02

F1 · derivative.exercise_date: On March 3, 2025, the reporting person was granted 25,000 stock options, vesting 6/48ths (15,625 shares) on September 2, 2025, and 1/48th every month thereafter until the stock option is fully vested on March 3, 2029.

SEC source: 0001437749-26-002527 · rdgdoc.xml · nonDerivative · entry 2

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 62,815

F1 · kind: Pro rata liquidating distribution from Tactic Pharma, LLC ("Tactic"), of which the reporting person is a non-controlling member. In prior reports, the reporting person reported beneficial ownership of 272,026 shares of Monopar Therapeutics Inc. common stock held by Tactic.

F2 · ownership.nature: Represents shares held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020.

SEC source: 0001437749-25-000098 · rdgdoc.xml · derivative · entry 1

RIOUX PATRICE · CIK 0001241033 · Acting Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,000

Underlying: Common Stock · 2,000 shares

Expires 2034-12-31

F1 · derivative.exercise_date: Stock Options vesting commenced on January 1, 2025 as follows: 1/12th of 2,000 options on January 31, 2025 and each subsequent month-end thereafter.

SEC source: 0001437749-25-000097 · rdgdoc.xml · derivative · entry 3

Cittadine Andrew · CIK 0001863624 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,074

Underlying: Common Stock · 1,790 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units.

F3 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F4 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F3 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F4 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

SEC source: 0001437749-25-000097 · rdgdoc.xml · nonDerivative · entry 2

Cittadine Andrew · CIK 0001863624 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,938

F1 · shares: Represents shares acquired on vesting and settlement of restricted stock units.

F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.

F1 · price: Represents shares acquired on vesting and settlement of restricted stock units.

F3 · balance_after: On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

SEC source: 0001437749-25-000097 · rdgdoc.xml · nonDerivative · entry 1

Cittadine Andrew · CIK 0001863624 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,659

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents shares acquired on vesting and settlement of restricted stock units.

SEC source: 0001437749-25-000096 · rdgdoc.xml · derivative · entry 4

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,879

Underlying: Common Stock · 4,895 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units.

F4 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 12,612 restricted stock units, vesting 6/48ths (1,577 shares) on June 30, 2021, and 3/48ths (788 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F5 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F6 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F4 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 12,612 restricted stock units, vesting 6/48ths (1,577 shares) on June 30, 2021, and 3/48ths (788 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F5 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F6 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

SEC source: 0001437749-25-000096 · rdgdoc.xml · nonDerivative · entry 2

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,848

F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.

SEC source: 0001437749-25-000096 · rdgdoc.xml · nonDerivative · entry 1

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,057

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents shares acquired on vesting and settlement of restricted stock units.

SEC source: 0001437749-24-037744 · rdgdoc.xml · nonDerivative · entry 1

TacticGem LLC · CIK 0001727358 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Tactic Gem, LLC distributed 611,079 shares to Gem Pharmaceuticals, LLC and 822,255 shares to Tactic Pharma, LLC for no consideration.

SEC source: 0001437749-24-032626 · rdgdoc.xml · nonDerivative · entry 1

Radhakrishnan Karthik · CIK 0001573327 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,550

F1 · price: The price reported in Column 4 is the Public offering price in the prospectus dated October 28, 2024.

SEC source: 0001437749-24-030535 · rdgdoc.xml · derivative · entry 3

Cittadine Andrew · CIK 0001863624 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,864

Underlying: Common Stock · 1,791 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units.

F1 · derivative.exercise_date: Effective on August 12, 2024, Monopar Therapeutics Inc effected a 5 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F4 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F5 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F1 · derivative.expiration_date: Effective on August 12, 2024, Monopar Therapeutics Inc effected a 5 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F4 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F5 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F1 · balance_after: Effective on August 12, 2024, Monopar Therapeutics Inc effected a 5 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

SEC source: 0001437749-24-030535 · rdgdoc.xml · nonDerivative · entry 2

Cittadine Andrew · CIK 0001863624 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,869

F2 · shares: Represents shares acquired on vesting and settlement of restricted stock units.

F3 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.

F2 · price: Represents shares acquired on vesting and settlement of restricted stock units.

F1 · balance_after: Effective on August 12, 2024, Monopar Therapeutics Inc effected a 5 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F4 · balance_after: On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

SEC source: 0001437749-24-030535 · rdgdoc.xml · nonDerivative · entry 1

Cittadine Andrew · CIK 0001863624 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,404

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Represents shares acquired on vesting and settlement of restricted stock units.

SEC source: 0001437749-24-030536 · rdgdoc.xml · derivative · entry 5

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,774

Underlying: Common Stock · 4,895 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units.

F1 · derivative.exercise_date: Effective on August 12, 2024, Monopar Therapeutics Inc effected a 5 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split

F6 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 12,612 restricted stock units, vesting 6/48ths (1,577 shares) on June 30, 2021, and 3/48ths (788 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F7 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F8 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F6 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 12,612 restricted stock units, vesting 6/48ths (1,577 shares) on June 30, 2021, and 3/48ths (788 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F7 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F8 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

SEC source: 0001437749-24-030536 · rdgdoc.xml · nonDerivative · entry 2

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,162

F3 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.

SEC source: 0001437749-24-030536 · rdgdoc.xml · nonDerivative · entry 1

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,080

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Represents shares acquired on vesting and settlement of restricted stock units.

SEC source: 0001437749-24-022213 · rdgdoc.xml · derivative · entry 1

Radhakrishnan Karthik · CIK 0001573327 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Commom Stock · 125,000 shares

Expires 2034-06-30

F1 · derivative.exercise_date: On July 1, 2024, the reporting person was granted 125,000 stock options, vesting 6/48ths (15,625 shares) on December 31, 2024, and 1/48th every month thereafter until the stock option is fully vested on July 1, 2028.